Therapix Biosciences - Two new cannabinoid programs

Therapix is expanding its cannabinoid-based clinical pipeline beyond neurological disorders to potentially treat obstructive sleep apnea (OSA), a chronic sleep disorder. The company is investigating the efficacy of THX-OSA01, an oral THC/PEA formulation, for the treatment of OSA in a 30-patient Phase IIa trial. In addition, Therapix is exploring the potential of a cannabinoid composition containing an antibacterial agent for the treatment of infectious diseases in preclinical trials. The company reported that the Phase IIa Tourette’s study will read out in H118 and the Phase I for mild cognitive impairment will begin in Q118.